143 related articles for article (PubMed ID: 38731819)
1.
Di-Iacovo N; Ferracchiato S; Pieroni S; Scopetti D; Castelli M; Piobbico D; Pierucci L; Gargaro M; Chiasserini D; Servillo G; Della-Fazia MA
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731819
[No Abstract] [Full Text] [Related]
2. HOPS and p53: thick as thieves in life and death.
Della-Fazia MA; Castelli M; Piobbico D; Pieroni S; Servillo G
Cell Cycle; 2020 Nov; 19(22):2996-3003. PubMed ID: 33112208
[TBL] [Abstract][Full Text] [Related]
3.
Ferracchiato S; Di-Iacovo N; Scopetti D; Piobbico D; Castelli M; Pieroni S; Gargaro M; Manni G; Brancorsini S; Della-Fazia MA; Servillo G
Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281239
[TBL] [Abstract][Full Text] [Related]
4. HOPS/TMUB1 retains p53 in the cytoplasm and sustains p53-dependent mitochondrial apoptosis.
Castelli M; Piobbico D; Chiacchiaretta M; Brunacci C; Pieroni S; Bartoli D; Gargaro M; Fallarino F; Puccetti P; Soddu S; Della-Fazia MA; Servillo G
EMBO Rep; 2020 Feb; 21(2):e48073. PubMed ID: 31867855
[TBL] [Abstract][Full Text] [Related]
5. HOPS/Tmub1 involvement in the NF-kB-mediated inflammatory response through the modulation of TRAF6.
Bellet MM; Pieroni S; Castelli M; Piobbico D; Fallarino F; Romani L; Della-Fazia MA; Servillo G
Cell Death Dis; 2020 Oct; 11(10):865. PubMed ID: 33060567
[TBL] [Abstract][Full Text] [Related]
6. Interference with the p53 family network contributes to the gain of oncogenic function of mutant p53 in hepatocellular carcinoma.
Schilling T; Kairat A; Melino G; Krammer PH; Stremmel W; Oren M; Müller M
Biochem Biophys Res Commun; 2010 Apr; 394(3):817-23. PubMed ID: 20233581
[TBL] [Abstract][Full Text] [Related]
7. The Ins and Outs of HOPS/TMUB1 in biology and pathology.
Della-Fazia MA; Castelli M; Piobbico D; Pieroni S; Servillo G
FEBS J; 2021 May; 288(9):2773-2783. PubMed ID: 32860479
[TBL] [Abstract][Full Text] [Related]
8. A role for c-myc in DNA damage-induced apoptosis in a human TP53-mutant small-cell lung cancer cell line.
Supino R; Perego P; Gatti L; Caserini C; Leonetti C; Colantuono M; Zuco V; Carenini N; Zupi G; Zunino F
Eur J Cancer; 2001 Nov; 37(17):2247-56. PubMed ID: 11677115
[TBL] [Abstract][Full Text] [Related]
9. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types.
Parikh N; Hilsenbeck S; Creighton CJ; Dayaram T; Shuck R; Shinbrot E; Xi L; Gibbs RA; Wheeler DA; Donehower LA
J Pathol; 2014 Apr; 232(5):522-33. PubMed ID: 24374933
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive Bioinformatic Investigation of TP53 Dysregulation in Diverse Cancer Landscapes.
Khan R; Pari B; Puszynski K
Genes (Basel); 2024 Apr; 15(5):. PubMed ID: 38790205
[TBL] [Abstract][Full Text] [Related]
11. Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas.
Donehower LA; Soussi T; Korkut A; Liu Y; Schultz A; Cardenas M; Li X; Babur O; Hsu TK; Lichtarge O; Weinstein JN; Akbani R; Wheeler DA
Cell Rep; 2019 Jul; 28(5):1370-1384.e5. PubMed ID: 31365877
[TBL] [Abstract][Full Text] [Related]
12. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM.
Song H; Hollstein M; Xu Y
Nat Cell Biol; 2007 May; 9(5):573-80. PubMed ID: 17417627
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity to PRIMA-1MET is associated with decreased MGMT in human glioblastoma cells and glioblastoma stem cells irrespective of p53 status.
Patyka M; Sharifi Z; Petrecca K; Mansure J; Jean-Claude B; Sabri S
Oncotarget; 2016 Sep; 7(37):60245-60269. PubMed ID: 27533246
[TBL] [Abstract][Full Text] [Related]
14. PLA2G16 is a mutant p53/KLF5 transcriptional target and promotes glycolysis of pancreatic cancer.
Xia W; Bai H; Deng Y; Yang Y
J Cell Mol Med; 2020 Nov; 24(21):12642-12655. PubMed ID: 32985124
[TBL] [Abstract][Full Text] [Related]
15. Dominant-negative p53 mutant R248Q increases the motile and invasive activities of oral squamous cell carcinoma cells.
Nakazawa S; Sakata KI; Liang S; Yoshikawa K; Iizasa H; Tada M; Hamada JI; Kashiwazaki H; Kitagawa Y; Yamazaki Y
Biomed Res; 2019; 40(1):37-49. PubMed ID: 30787262
[TBL] [Abstract][Full Text] [Related]
16. A common gain of function of p53 cancer mutants in inducing genetic instability.
Liu DP; Song H; Xu Y
Oncogene; 2010 Feb; 29(7):949-56. PubMed ID: 19881536
[TBL] [Abstract][Full Text] [Related]
17. TNF-α modulates genome-wide redistribution of ΔNp63α/TAp73 and NF-κB cREL interactive binding on TP53 and AP-1 motifs to promote an oncogenic gene program in squamous cancer.
Si H; Lu H; Yang X; Mattox A; Jang M; Bian Y; Sano E; Viadiu H; Yan B; Yau C; Ng S; Lee SK; Romano RA; Davis S; Walker RL; Xiao W; Sun H; Wei L; Sinha S; Benz CC; Stuart JM; Meltzer PS; Van Waes C; Chen Z
Oncogene; 2016 Nov; 35(44):5781-5794. PubMed ID: 27132513
[TBL] [Abstract][Full Text] [Related]
18. p53 in breast cancer subtypes and new insights into response to chemotherapy.
Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
[TBL] [Abstract][Full Text] [Related]
19. Reactivation of mutant p53 by a dietary-related compound phenethyl isothiocyanate inhibits tumor growth.
Aggarwal M; Saxena R; Sinclair E; Fu Y; Jacobs A; Dyba M; Wang X; Cruz I; Berry D; Kallakury B; Mueller SC; Agostino SD; Blandino G; Avantaggiati ML; Chung FL
Cell Death Differ; 2016 Oct; 23(10):1615-27. PubMed ID: 27258787
[TBL] [Abstract][Full Text] [Related]
20. TP53 mutations, expression and interaction networks in human cancers.
Wang X; Sun Q
Oncotarget; 2017 Jan; 8(1):624-643. PubMed ID: 27880943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
